Literature DB >> 3818939

Ability of ciprofloxacin but not pipemidic acid to differentiate all three biovariants of Mycobacterium fortuitum from Mycobacterium chelonae.

L C Steele, R J Wallace.   

Abstract

When tested against 312 clinical isolates of rapidly growing mycobacteria, the quinolone pipemidic acid correctly separated Mycobacterium chelonae (M. chelonei) from Mycobacterium fortuitum biovar fortuitum but not from biovar peregrinum or the third biovar complex. The new 4-quinolone ciprofloxacin correctly separated all three biovars of M. fortuitum from M. chelonae and appears to provide a better taxonomic test.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3818939      PMCID: PMC265926          DOI: 10.1128/jcm.25.2.456-457.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  A study of Mycobacterium fortuitum (ranae).

Authors:  S R Pattyn; M Magnusson; J L Stanford; J M Grange
Journal:  J Med Microbiol       Date:  1974-02       Impact factor: 2.472

2.  Simple, new test for rapid differentiation of the Mycobacterium fortuitum complex.

Authors:  M J Casal; F C Rodriguez
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

3.  Disk diffusion testing with polymyxin and amikacin for differentiation of Mycobacterium fortuitum and Mycobacterium chelonei.

Authors:  R J Wallace; J M Swenson; V A Silcox; R C Good
Journal:  J Clin Microbiol       Date:  1982-12       Impact factor: 5.948

4.  Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.

Authors:  J M Swenson; R J Wallace; V A Silcox; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

5.  Identification of Mycobacterium fortuitum and Mycobacterium chelonei.

Authors:  V Lévy-Frébault; M Daffé; K S Goh; M A Lanéelle; C Asselineau; H L David
Journal:  J Clin Microbiol       Date:  1983-05       Impact factor: 5.948

6.  In vitro susceptibility of Mycobacterium fortuitum to non-antituberculous antibacterial agents.

Authors:  M J Casal; F C Rodriguez
Journal:  Ann Microbiol (Paris)       Date:  1983 Jan-Feb

7.  Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.

Authors:  R J Wallace; J M Swenson; V A Silcox; M G Bullen
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

8.  Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents.

Authors:  R J Wallace; J R Dalovisio; G A Pankey
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

9.  Antimicrobial susceptibility testing of Mycobacterium fortuitum complex.

Authors:  D F Welch; M T Kelly
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

10.  Identification of clinically significant Mycobacterium fortuitum complex isolates.

Authors:  V A Silcox; R C Good; M M Floyd
Journal:  J Clin Microbiol       Date:  1981-12       Impact factor: 5.948

View more
  9 in total

Review 1.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

2.  Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.

Authors:  R J Wallace; G Bedsole; G Sumter; C V Sanders; L C Steele; B A Brown; J Smith; D R Graham
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

3.  Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid.

Authors:  R J Wallace; B A Brown; G O Onyi
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

4.  Polyphasic characterization reveals that the human pathogen Mycobacterium peregrinum type II belongs to the bovine pathogen species Mycobacterium senegalense.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; June Brown; Arnold G Steigerwalt; Leslie Hall; Gail Woods; Joann Cloud; Linda Mann; Rebecca Wilson; Christopher Crist; Kenneth C Jost; Dorothy E Byrer; Jane Tang; Jason Cooper; Elena Stamenova; Brian Campbell; Joyce Wolfe; Christine Turenne
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Sensitivity of fluorochrome microscopy for detection of Mycobacterium tuberculosis versus nontuberculous mycobacteria.

Authors:  P W Wright; R J Wallace; N W Wright; B A Brown; D E Griffith
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

6.  Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism.

Authors:  R J Wallace; V A Silcox; M Tsukamura; B A Brown; J O Kilburn; W R Butler; G Onyi
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

7.  PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria.

Authors:  V A Steingrube; J L Gibson; B A Brown; Y Zhang; R W Wilson; M Rajagopalan; R J Wallace
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

8.  Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones.

Authors:  I Guillemin; E Cambau; V Jarlier
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 9.  Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.